Sonoma Pharmaceuticals (SNOA) Other Non-Current Liabilities (2011 - 2025)

Sonoma Pharmaceuticals' Other Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $5.5 million for Q4 2025.

• In Q4 2025, Other Non-Current Liabilities rose 8.52% year-over-year to $5.5 million; the TTM figure through Dec 2025 stood at $5.5 million (up 8.52% YoY), while the FY2025 annual figure was $5.1 million, up 9.17% from the prior year.
• Other Non-Current Liabilities was $5.5 million for Q4 2025 at Sonoma Pharmaceuticals, up from $5.4 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $5.5 million in Q4 2025 to a low of $3.5 million in Q1 2021.
• Historically, Other Non-Current Liabilities has averaged $4.4 million across 5 years, with a median of $4.4 million in 2023.
• The sharpest annual moves came in 2021 and 2025: Other Non-Current Liabilities climbed 12.85% in 2021, then grew 8.52% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $3.8 million in 2021, then rose by 9.22% to $4.1 million in 2022, then gained by 12.06% to $4.6 million in 2023, then rose by 9.69% to $5.0 million in 2024, then climbed by 8.52% to $5.5 million in 2025.
• The last three Other Non-Current Liabilities figures came in at $5.5 million (Q4 2025), $5.4 million (Q3 2025), and $5.2 million (Q2 2025), per Business Quant data.